Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer

• Príomhchruthaitheoirí: Roshni D. Kalachand (Údar), Ciaran O'Riain (Údar), Sinead Toomey (Údar), Aoife Carr (Údar), Kirsten M. Timms (Údar), Sharon O'Toole (Údar), Stephen Madden (Údar), Mark Bates (Údar), John J. O'Leary (Údar), Noreen Gleeson (Údar), Dearbhaile O'Donnell (Údar), Liam Grogan (Údar), Oscar Breathnach (Údar), Angela Farrelly (Údar), Britta Stordal (Údar), Bryan T. Hennessy (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Korean Society of Obstetrics and Gynecology, 2020-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objective The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2 mutations and BRCA1 methylation in women with OC. Met...